GC
TGTX icon

Grimes & Company’s TG Therapeutics TGTX Stock Holding History

Grimes & Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Hold
6,100
– – 0.01% 364
2026
Q1 		$203K Buy
+6,100
New +$182K 0.01% 417
2025
Q4 		– Sell
-6,100
Closed -$220K – 483
2025
Q3 		$220K Hold
6,100
– – 0.01% 427
2025
Q2 		$220K Hold
6,100
– – 0.01% 394
2025
Q1 		$241K Buy
+6,100
New +$205K 0.01% 321

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Grimes & Company's TGTX Position: Q2 2026 in Review

Grimes & Company held its TG Therapeutics (TGTX) position steady in Q2 2026 at 6,100 shares worth $335K. The position accounts for 0.01% of the portfolio, ranked #364.

Grimes & Company first reported a position in TGTX in Q1 2025 and has held it in 5 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Grimes & Company held 6,100 shares of TG Therapeutics worth $335K as of Q2 2026.
  • Grimes & Company left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #364 holding.
  • Grimes & Company first reported a position in TG Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.